@article{7a3d217b182447898ae28fbf3b091624,
title = "Harnessing Natural Killer Cell Function for Genitourinary Cancers",
abstract = "Natural killer (NK) cells are potently cytolytic innate lymphocytes involved in the immune surveillance of tumors and virally infected cells. Although much progress has been made in manipulating the ability of T cells to recognize and eliminate tumors, a comprehensive understanding of NK-cell infiltration into solid tumors, and their amenability to immunomodulation, remains incomplete. This article discusses recent studies showing that urologic tumors are infiltrated by NK cells and that these NK cells are often dysfunctional, but that strategies interfering with inhibitory axes have significant potential to alleviate this dysfunction.",
keywords = "Bladder cancer, Genitourinary cancer, Immunotherapy, NK cells, Natural killer cells, RCC, Renal cancer",
author = "Nina Bhardwaj and Farkas, {Adam M.} and Zeynep Gul and Sfakianos, {John P.}",
note = "Funding Information: This work was funded by a Translational Team Science Award from the Department of Defense (CA181008) to N. Bhardwaj and J.P. Sfakianos, and National Institutes of Health R01 CA201189 to N. Bhardwaj. N. Bhardwaj is an advisory board member for Neon, Tempest, CPS Companion Diagnostics, Curevac, Primevax, Novartis, Array BioPharma, Roche, Avidea, Boehringer Ingelheim, Rome Therapeutics, and Roswell Park. N. Bhardwaj is an extramural member of the Parker Institute for Cancer Immunotherapy, and has received research support from Celldex, Genentech, Oncovir, and Regeneron. A.M. Farkas, Z. Gul, and J.P. Sfakianos have no disclosures to report. Funding Information: This work was funded by a Translational Team Science Award from the Department of Defense (CA181008) to N. Bhardwaj and J.P. Sfakianos, and National Institutes of Health R01 CA201189 to N. Bhardwaj. N. Bhardwaj is an advisory board member for Neon, Tempest, CPS Companion Diagnostics, Curevac, Primevax, Novartis, Array BioPharma, Roche, Avidea, Boehringer Ingelheim, Rome Therapeutics, and Roswell Park. N. Bhardwaj is an extramural member of the Parker Institute for Cancer Immunotherapy, and has received research support from Celldex , Genentech , Oncovir , and Regeneron . A.M. Farkas, Z. Gul, and J.P. Sfakianos have no disclosures to report. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = nov,
doi = "10.1016/j.ucl.2020.07.002",
language = "English",
volume = "47",
pages = "433--442",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "4",
}